加利福尼亚州尔湾 - 市值达18.2亿美元的眼科护理和传染病预防专业公司Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS )今日宣布启动1亿美元普通股的公开发行。根据 InvestingPro ...

Tarsus Pharmaceuticals (TARS) announced the commencement of an underwritten public offering of $100M of shares of its common stock. All shares ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”) today announced the pricing of an upsized ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Free Report) has been given an average recommendation of “Buy” by the seven ...

Jefferies raised the firm’s price target on Tarsus Pharmaceuticals (TARS) to $58 from $54 and keeps a Buy rating on the shares. The firm says ...

U.S. Customs and Border Protection (CBP) has claimed an object that people from Quinlan say fell from the sky on Tuesday ...

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. Its product candidate, TP-03, is a ...

Tarsus Pharmaceuticals sees growth with Xdemvy's $180M sales in 2024. Read this article to know what makes TARS stock a BUY for growth investors.

Tarsus Pharmaceuticals Inc (NASDAQ:TARS) reported over $180 million in net product sales for 2024, exceeding expectations. The company expanded its sales force from 100 to 150 representatives ...